Consensus statement on safety measures for pressurized intraperitoneal aerosol chemotherapy

Abstract Objectives Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising treatment for peritoneal cancer that entails, however, potential risks for the caregivers in the operating room (OR). This study aimed to reach a consensus within the PIPAC community on a comprehensive safety protocol. Methods Active PIPAC centers were invited to participate in a two-round Delphi process on 43 predefined items: concise summaries of the existing evidence were presented together with questions formulated using the population, intervention, comparator, and outcome framework. According to the Grading of Recommendations Assessment, Development, and Evaluation, the strength of recommendation was voted by panelists, accepting a consensus threshold of ≥50% of the agreement for any of the four grading options, or ≥70% in either direction. Results Forty-seven out of 66 invited panelists answered both rounds (response rate 76%). The consensus was reached for 41 out of 43 items (95.3%). Strong and weak recommendations were issued for 30 and 10 items, respectively. A positive consensual recommendation was issued to activate laminar airflow without specific strength, neither strong nor weak. No consensus was reached for systematic glove change for caregivers with a high risk of exposure and filtering facepiece mask class 3 for caregivers with low risk of exposure. Conclusions A high degree of consensus was reached for a comprehensive safety protocol for PIPAC, adapted to the risk of exposure for the different caregivers in the OR. This consensus can serve as a basis for education and help reach a high degree of adherence in daily practice.

[1]  B. Rau,et al.  Current practice and perceptions of safety protocols for the use of intraperitoneal chemotherapy in the operating room: results of the IP-OR international survey , 2021, Pleura and Peritoneum.

[2]  M. Lahaye,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC) , 2021, Annals of Surgical Oncology.

[3]  M. Pocard,et al.  Standardizing training for Pressurized Intraperitoneal Aerosol Chemotherapy. , 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  O. Sgarbura,et al.  Non-medical caregivers and the use of intraperitoneal chemotherapy in the operating theatre: A survey on the perception of safety. , 2020, Journal of visceral surgery.

[5]  D. Lobo,et al.  Recommendations from the ERAS® Society for standards for the development of enhanced recovery after surgery guidelines , 2019, BJS open.

[6]  P. Diemunsch,et al.  Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in an operating room without laminar airflow. , 2019, Journal of visceral surgery.

[7]  F. Lordick,et al.  [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures]. , 2019, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[8]  G. Nadiradze,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) , 2019 .

[9]  S. Ndaw,et al.  Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination. , 2018, Toxicology letters.

[10]  D. Nowak,et al.  Occupational exposure to cisplatin/oxaliplatin during Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)? , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  C. Tempfer,et al.  How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures , 2018, Journal of Gastrointestinal Surgery.

[12]  O. Glehen,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Non-resectable Peritoneal Carcinomatosis (with Video) , 2018, Journal of Gastrointestinal Surgery.

[13]  P. Sessink,et al.  Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) , 2017, Pleura and peritoneum.

[14]  N. Demartines,et al.  Pressurized IntraPeritoneal Aerosol Chemotherapy - Practical aspects. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  N. Demartines,et al.  Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis , 2017, The British journal of surgery.

[16]  M. Mortensen,et al.  Environmental safety during the administration of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) , 2016, Pleura and peritoneum.

[17]  J. Spiliotis,et al.  Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). , 2016, Surgical oncology.

[18]  W. Solass,et al.  [Occupational Health Aspects of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC): Confirmation of Harmlessness]. , 2014, Zentralblatt fur Chirurgie.

[19]  S. Msika,et al.  Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  Urs Giger-Pabst,et al.  Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.

[21]  David Rind,et al.  GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. , 2013, Journal of clinical epidemiology.

[22]  W. Solass,et al.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects , 2013, Annals of Surgical Oncology.

[23]  D. Nowak,et al.  Low surface contamination by cis/oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.